Comparing Effect of Double Dose of Hepatitis B Vaccine Verses Conventional Dose in Patients with Chronic Liver Disease
Objective: To compare the effectiveness of double dose hepatitis B vaccine in patients with chronic liver disease versus conventional-dose
Study design: Randomized control trial
Place and Duration: Six months after the approval of synopsis i.e 15th March 2017 to 14th September 2017, Department of General Medicine, FFH, Rawalpindi
Methodology: A total of one hundred and sixteen (n=116) diagnosed cases of chronic liver disease of either gender between age 30 to 70 years were enrolled and were divided into two groups one received a double dose (2 ml, 40 Âµg) and the other received a conventional dose (1 ml, 20 Âµg). Quantitative anti-HBs was measured at three months in both groups.
Mean with standard deviation calculated for quantitative variables like age, anti-HBs level one month after 3rd dose and frequency and percentages in case of categorical variables like gender and effectiveness. Chi-square test was used to determine the significant difference in both groups regarding the effectiveness of vaccination. A p-value â‰¤0.05 was taken significantly.
Results: In patients who received double dose seroprotection (anit HBs >10 IU/ml) was achieved in 93.1% (n=54/58) patients, while the percentage was 77.6% (n=45/58) in patients who received a conventional dose (P<0.05).
Conclusions: Seroprotection (anit HBs >10 IU/ml) at three months was significantly better in patients who received the double dose of vaccine. Vaccine effectiveness was significantly better in younger age group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.